250 related articles for article (PubMed ID: 21240857)
21. Bilateral intravitreal bevacizumab injection for exudative age-related macular degeneration: effect of baseline visual acuity.
Jonas JB; Tao Y; Rensch F
J Ocul Pharmacol Ther; 2011 Aug; 27(4):401-5. PubMed ID: 21810019
[TBL] [Abstract][Full Text] [Related]
22. FLAT IRREGULAR PIGMENT EPITHELIUM DETACHMENT IN CENTRAL SEROUS CHORIORETINOPATHY: A Form of Pachychoroid Neovasculopathy?
Hwang H; Kim JY; Kim KT; Chae JB; Kim DY
Retina; 2020 Sep; 40(9):1724-1733. PubMed ID: 31584559
[TBL] [Abstract][Full Text] [Related]
23. Intravitreal bevacizumab in the management of subretinal fluid associated with choroidal osteoma.
Song JH; Bae JH; Rho MI; Lee SC
Retina; 2010 Jun; 30(6):945-51. PubMed ID: 20531145
[TBL] [Abstract][Full Text] [Related]
24. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration.
Ach T; Hoeh AE; Ruppenstein M; Kretz FT; Dithmar S
Retina; 2010 Oct; 30(9):1420-5. PubMed ID: 20543764
[TBL] [Abstract][Full Text] [Related]
25. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.
Freeman WR; Kozak I; Yuson RM; Nigam N; Cheng L; Mojana F
Retina; 2011 Oct; 31(9):1812-8. PubMed ID: 21866073
[TBL] [Abstract][Full Text] [Related]
26. Intravitreal aflibercept for choroidal neovascularisation complicating chronic central serous chorioretinopathy.
Broadhead GK; Chang A
Graefes Arch Clin Exp Ophthalmol; 2015 Jun; 253(6):979-81. PubMed ID: 25547617
[No Abstract] [Full Text] [Related]
27. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study.
Artunay O; Yuzbasioglu E; Rasier R; Sengul A; Bahcecioglu H
Curr Eye Res; 2010 Feb; 35(2):91-8. PubMed ID: 20136418
[TBL] [Abstract][Full Text] [Related]
28. Rapid and sustained resolution of serous retinal detachment in Sturge-Weber syndrome after single injection of intravitreal bevacizumab.
Shoeibi N; Ahmadieh H; Abrishami M; Poorzand H
Ocul Immunol Inflamm; 2011 Oct; 19(5):358-60. PubMed ID: 21823932
[TBL] [Abstract][Full Text] [Related]
29. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy.
Schaal KB; Hoeh AE; Scheuerle A; Schuett F; Dithmar S
Eur J Ophthalmol; 2009; 19(4):613-7. PubMed ID: 19551677
[TBL] [Abstract][Full Text] [Related]
30. Intravitreal bevacizumab for choroidal neovascularization secondary to laser photocoagulation for central serous chorioretinopathy.
Pikkel J; Rumelt S
Eur J Ophthalmol; 2012; 22(3):488-91. PubMed ID: 21928270
[TBL] [Abstract][Full Text] [Related]
31. Intravitreal bevacizumab to treat choroidal neovascularization following photodynamic therapy in central serous choroidopathy.
Montero JA; Ruiz-Moreno JM; Fernandez-Muñoz M
Eur J Ophthalmol; 2011; 21(4):503-5. PubMed ID: 21279982
[TBL] [Abstract][Full Text] [Related]
32. Bevacizumab for Coats' disease with exudative retinal detachment and risk of vitreoretinal traction.
Ramasubramanian A; Shields CL
Br J Ophthalmol; 2012 Mar; 96(3):356-9. PubMed ID: 21653215
[TBL] [Abstract][Full Text] [Related]
33. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
[TBL] [Abstract][Full Text] [Related]
34. Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics.
Rush RB; Simunovic MP; Vandiver L; Aragon AV; Ysasaga JE
Retina; 2014 May; 34(5):846-52. PubMed ID: 24240560
[TBL] [Abstract][Full Text] [Related]
35. Combined intravitreal bevacizumab and triamcinolone in exudative age-related macular degeneration.
Jonas JB; Libondi T; Golubkina L; Spandau UH; Schlichtenbrede F; Rensch F
Acta Ophthalmol; 2010 Sep; 88(6):630-4. PubMed ID: 19432871
[TBL] [Abstract][Full Text] [Related]
36. Bevacizumab in macular serous detachments associated with Waldenstrom's macroglobulinemia.
Kapoor KG; Wagner MS
Ophthalmic Surg Lasers Imaging Retina; 2015 Jan; 46(1):95-7. PubMed ID: 25559519
[TBL] [Abstract][Full Text] [Related]
37. High-dose ranibizumab therapy for vascularized pigment epithelial detachment.
Chan CK; Abraham P; Sarraf D
Eye (Lond); 2012 Jun; 26(6):882-5. PubMed ID: 22576827
[TBL] [Abstract][Full Text] [Related]
38. Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients.
Kim GA; Rim TH; Lee SC; Byeon SH; Koh HJ; Kim SS; Lee CS
Eye (Lond); 2015 Jun; 29(6):732-40; quiz 741. PubMed ID: 25952951
[TBL] [Abstract][Full Text] [Related]
39. The treatment of recurrent central serous chorioretinopathy with intravitreal bevacizumab.
Lee ST; Adelman RA
J Ocul Pharmacol Ther; 2011 Dec; 27(6):611-4. PubMed ID: 21810026
[TBL] [Abstract][Full Text] [Related]
40. Bevacizumab therapy and multimodal ultrawide-field imaging in immunogammopathy maculopathy secondary to Waldenström's macroglobulinemia.
Xu LT; Courtney RJ; Ehlers JP
Ophthalmic Surg Lasers Imaging Retina; 2015 Feb; 46(2):262-5. PubMed ID: 25707055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
